Desonide hydrogel: Advances in vehicle technology

Expert Review of Dermatology

Volumn 4, Issue 1, 2009, Pages 23-27

  Gelbard, Christina M ^a   Herbert, Adelaide A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Atopic dermatitis; Desonate ; Desonide; Topical corticosteroid

Indexed keywords

DESONIDE; DODECYL SULFATE SODIUM; STEROID;

ACNE; ADRENAL DISEASE; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; BLISTER; BURNING SENSATION; CATARACT; CLINICAL TRIAL; CONTACT DERMATITIS; CREAM; CUSHING SYNDROME; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FACE DISORDER; FOOT DISEASE; GROWTH RETARDATION; HUMAN; HYDROGEL; HYPOPHYSIS DISEASE; HYPOPIGMENTATION; HYPOTHALAMUS DISEASE; LOTION; MITOSIS INHIBITION; NEUROENDOCRINE DISEASE; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RASH; SCAR; SECONDARY INFECTION; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN DISEASE; SKIN INFECTION; SKIN IRRITATION; SLEEP DISORDER; STRIA; SWELLING; TELANGIECTASIA; VASOCONSTRICTION; XEROSIS;

EID: 69949180713     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.4.1.23     Document Type: Article

References (22)

1. Smith EB, Gregory JF, Bartruff JK. Desonide, a potent nonfluorinated topical steroid, vasoconstriction assay and clinical trial. South Med. J. 66, 325-329 (1973).
2. Kahanek N, Gelbard C, Hebert A. Desonide: a review of formulations, efficacy and safety. Expert Opin. Investig. Drugs 17, 1097-1104 (2008).
3. Phillips B, Sanen F, Leeling J et al. The physical, animal and human pharmacologic and toxicologic properties of desonide, a new, topically active, antiinflammatory steroid. Toxicol. Appl. Pharmacol. 20, 522-537 (1971).
4. Lucky AW, Grote, GD, Williams JL et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 59, 151-153 (1997).
5. Wong VK, Fuchs B, Lebwohl M. Overview on desonide 0.05%: a clinical safety profile. J. Drugs Dermatol. 3(4), 393-397 (2004).
6. Kircik L, Del Rosso J. A novel hydrogel vehicle formulated for the treatment of atopic dermatitis. J. Drugs Dermatol. 6, 718-722 (2007).
7. Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J. Drugs Dermatol. 6, 175-181 (2007).
8. Desonate® (desonide) Gel 0.05%. Package insert. SkinMedica, Inc. (2007).
9. Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm. Venereol. 151(Suppl.), 11-19 (1989).
10. Wolverton S. Comprehensive Dermatologic Drug Therapy (2nd Edition). Elsevier, PA, USA (2007).
11. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol. 275, 71-78 (2007).
12. Ahluwalia A. Topical glucocorticoids and the skin - mechanisms of action: an update. Mediators Inflamm. 7, 183-193 (1998).
13. Hebert AA, Cook-Bolden FE, Ford RO, Gotz V. Early relief of atopic dermatitis: symptoms with a novel hydrogel formulation of desonide 0.05% in pediatric subjects. Presented at: 66th Annual Meeting of the American Academy of Dermatology. San Antonio, TX, USA, 1-5 February 2008 (Poster 614).
14. Data on file. SkinMedica, Inc.
15. Trookman NS, Rizer,RL Ford R, Trancik RJ. Atopic dermatitis: advantages of a novel hydrogel vehicle. Presented at: 65th Annual Meeting of the American Academy of Dermatology. Washington DC, USA, 2-6 February 2007 (Poster 730).
16. Brodell RT, O'Brien MJ Jr. Topical corticosteroid-induced acne. Three treatment strategies to break the 'addiction' cycle. Postgrad. Med. 106, 225-226, 229 (1999).
17. Eichenfield LF, Basu S, Calvarese B, Trancik RJ. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr. Dermatol. 24, 289-295 (2007).
18. Foti C, Cassano N, Vena GA. Evaluation of cross-reactivity between budesonide and desonide. Contact Derm. 47, 109-110 (2002).
19. Sturtz RP, Rau RC. Contact dermatitis to desonide. Arch. Dermatol. 119, 1023 (1983).
20. Rivara G, Tomb RR, Foussereau J. Allergic contact dermatitis from topical corticosteroids. Contact Derm. 21, 83-91 (1989).
21. Lucky AW, Grote GD, Williams JL et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 59, 151-153 (1997).
22. Lebrun-Vignes B, Legrain V, Amoric J, Taieb A. [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis]. Ann. Dermatol. Venereol. 127, 590-595 (2000).